Following the release of a Nordic study, Finland joins Sweden and Denmark in pausing the distribution of the Moderna COVID-19 vaccine for young adult males (under 30) after reports of a rare cardiovascular side effect. The unpublished study will be sent to the European Medicines Agency (EMA) for further review. In very rare circumstances, the EMA’s safety committee ruled that similar inflammatory heart conditions could occur with the with Spikevax or the Pfizer/BioNTech vaccine in July. US regulators, EU regulators and the WHO (World Health Organization) have emphasized the efficacy and benefits of the mRNA technology used in Moderna and Pfizer-BioNTech to prevent COVID-19. Finland now plans to inoculate young males under 30 with the Pfizer vaccine.
Read more here.